IDEXX Laboratories, Inc. $IDXX Stock: Apollon Wealth Management LLC Reduces Holdings

Key Points

• Apollon Wealth Management cut its IDEXX Laboratories stake by 35.3% in the third quarter, selling 2,074 shares and retaining 3,799 shares worth approximately $1.98 million. Institutional investors and hedge funds collectively own 87.84% of the company.
• IDEXX reported quarterly revenue of $1.22 billion and earnings of $4.27 per share, exceeding analyst expectations, while revenue increased 9.7% year over year. The company issued fiscal 2026 EPS guidance of $14.69 to $14.94.
• Analyst sentiment remains positive overall, with nine Buy ratings and six Hold ratings producing a consensus “Moderate Buy” rating and an average price target of $727.69, despite several recent target-price reductions.

Apollon Wealth Management LLC trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 35.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 3,799 shares of the company's stock after selling 2,074 shares during the quarter. Apollon Wealth Management LLC's holdings in IDEXX Laboratories were worth $1,984,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its position in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after acquiring an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $29,000. Arlington Trust Co LLC increased its stake in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock valued at $32,000 after acquiring an additional 19 shares during the last quarter. Finally, Pin Oak Investment Advisors Inc. bought a new position in IDEXX Laboratories in the second quarter valued at approximately $49,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 2.3%

Shares of IDXX stock opened at $575.98 on Friday. The firm has a market capitalization of $45.38 billion, a P/E ratio of 40.50 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock's fifty day simple moving average is $534.16 and its 200 day simple moving average is $574.96.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the previous year, the firm posted $3.50 EPS. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. Jefferies Financial Group decreased their price target on IDEXX Laboratories from $795.00 to $705.00 and set a "buy" rating on the stock in a research note on Tuesday, October 20th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. The Goldman Sachs Group began coverage on IDEXX Laboratories in a research report on Friday, October 16th. They set a "buy" rating and a $740.00 price objective for the company. Finally, Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Nine analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $727.69.

Insider Transactions at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company's stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.79% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.